The new VAC2VAC project - "Vaccine batch to vaccine batch comparison by consistency testing" – officially launched on the 1st March 2016, brings together 20 public and private partners including the European Commission Joint Research Centre's European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM).
VAC2VAC is funded under the Innovative Medicines Initiative 2 (IMI 2), a Joint Undertaking of the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The project will provide data to support the consistency approach for quality control of established vaccines for human and veterinary use. The consistency approach moves away from the current focus on final product control often relying on animal testing. In the light of this, VAC2VAC partners will develop, optimise and evaluate non-animal methods, e.g. physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines, in collaboration and consultation with regulatory agencies.
The JRC's EURL ECVAM is participating in the project as leader of the work package related to validation, and will also support project activities related to international dissemination, harmonisation and regulatory acceptance of consistency approaches.
Press release: VAC2VAC launch
More information is available on the VAC2VAC website.